Mirjana Urosevic

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Disseminated ulcerating lupus panniculitis emerging under interferon therapy of hairy cell leukemia: treatment or disease-related?
    Mirjana Urosevic-Maiwald
    University Hospital Zurich
    Dermatol Online J 20:21727. 2014
  2. doi request reprint Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer
    Mirjana Urosevic-Maiwald
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Int J Dermatol 51:864-7. 2012
  3. ncbi request reprint Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Blood 103:1796-8. 2004
  4. ncbi request reprint Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    J Natl Cancer Inst 97:1143-53. 2005
  5. ncbi request reprint CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich 8091, Switzerland
    Hum Pathol 36:1020-4. 2005
  6. ncbi request reprint Expression of melanoma-associated antigens in melanoma cell cultures
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Exp Dermatol 14:491-7. 2005
  7. ncbi request reprint HLA-G and IL-10 expression in human cancer--different stories with the same message
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, Zurich 8091, Switzerland
    Semin Cancer Biol 13:337-42. 2003
  8. ncbi request reprint HLA-G in skin cancer: a wolf in sheep's clothing?
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Hum Immunol 64:1073-80. 2003
  9. ncbi request reprint Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas
    Mirjana Urosevic
    Address UniversitätsSpital Zürich, Dermatologische Klinik, Gloriastrasse 31, 8091 Zurich Switzerland
    Curr Opin Investig Drugs 8:493-8. 2007
  10. ncbi request reprint HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy
    M Urosevic
    Department of Dermatology, University Hospital Zurich, Switzerland
    Clin Exp Dermatol 30:422-5. 2005

Collaborators

Detail Information

Publications48

  1. ncbi request reprint Disseminated ulcerating lupus panniculitis emerging under interferon therapy of hairy cell leukemia: treatment or disease-related?
    Mirjana Urosevic-Maiwald
    University Hospital Zurich
    Dermatol Online J 20:21727. 2014
    ..Our report is the first one to show induction of lupus panniculitis during interferon therapy of hairy cell leukemia and its presumable continued exacerbation by the latter. ..
  2. doi request reprint Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer
    Mirjana Urosevic-Maiwald
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Int J Dermatol 51:864-7. 2012
    ..Every skin condition in a patient with cancer leading to extensive exfoliation of the skin should alert the oncologist of a possibility of drug-induced SJS or TEN...
  3. ncbi request reprint Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Blood 103:1796-8. 2004
    ..Together with the expression of IL-10, HLA-G might be one of the factors accounting for the evasion of immunosurveillance, thus contributing to aggressive phenotype of these lymphoma entities...
  4. ncbi request reprint Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    J Natl Cancer Inst 97:1143-53. 2005
    ..We focused on plasmacytoid predendritic cells (PDCs), the primary producer of interferon alpha (IFN-alpha) after imiquimod activation in vitro...
  5. ncbi request reprint CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich 8091, Switzerland
    Hum Pathol 36:1020-4. 2005
    ..MxA protein, representing the surrogate marker for lesional type I interferon activity, was expressed in 4 of 5 evaluated cases. Our findings further substantiate the putative pDC origin of CD4+CD56+ HNs...
  6. ncbi request reprint Expression of melanoma-associated antigens in melanoma cell cultures
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Exp Dermatol 14:491-7. 2005
    ..05-0.001). Elucidation of the MAA expression patterns and the kinetics within the same patient as well as during the course of the disease may help improve current and develop new immunotherapeutic strategies...
  7. ncbi request reprint HLA-G and IL-10 expression in human cancer--different stories with the same message
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, Zurich 8091, Switzerland
    Semin Cancer Biol 13:337-42. 2003
    ..This article reviews the current literature on this topic and provides new insights into the role of HLA-G and IL-10 in cancer...
  8. ncbi request reprint HLA-G in skin cancer: a wolf in sheep's clothing?
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Hum Immunol 64:1073-80. 2003
    ..This review will concentrate on induction and expression of this nonclassical class I molecule in different skin cancer types presenting existing experimental evidence on this topic...
  9. ncbi request reprint Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas
    Mirjana Urosevic
    Address UniversitätsSpital Zürich, Dermatologische Klinik, Gloriastrasse 31, 8091 Zurich Switzerland
    Curr Opin Investig Drugs 8:493-8. 2007
    ..A phase I/II clinical trial in CTCL and CBCL was recently completed, and in November 2006 Transgene initiated a phase II clinical trial in CBCL...
  10. ncbi request reprint HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy
    M Urosevic
    Department of Dermatology, University Hospital Zurich, Switzerland
    Clin Exp Dermatol 30:422-5. 2005
    ..After radiotherapy, immunobiology of BCC may change resulting in the down-regulation of HLA-G expression on tumor and on tumor-infiltrating cells...
  11. ncbi request reprint HLA-G in the skin--friend or foe?
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland
    Semin Cancer Biol 17:480-4. 2007
    ..This review focuses on the functionality of HLA-G in the skin and summarizes available data obtained from studies performed in skin cancer and inflammatory dermatoses...
  12. pmc Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    J Clin Invest 117:2834-46. 2007
    ..Biological effects of type I IFNs seem to enhance those set in motion by the transgene, in our case IFN-gamma. This combination may prove to be of therapeutic importance in cytokine gene transfer using Ads...
  13. doi request reprint Human leukocyte antigen-G and cancer immunoediting
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Cancer Res 68:627-30. 2008
    ..In this review, we summarize the evidence that up-regulation of the nonclassic human leukocyte antigen (HLA) class I molecule HLA-G in tumor cells plays an important role in cancer and immune escape...
  14. ncbi request reprint Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 10:4959-70. 2004
    ..Via interaction with Toll-like receptor 7 on immune cells, imiquimod induces local production of cytokines, such as interferon (IFN)-alpha...
  15. ncbi request reprint Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients
    Karin Murer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Melanoma Res 14:257-62. 2004
    ..0038). This could not be shown for any of the markers tested by FACS. Our results suggest that the expression of Melan-A/MART-1 in patient-derived cell cultures may help to identify a group of melanoma patients with prolonged survival...
  16. doi request reprint Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Mol Ther 16:985-94. 2008
    ..Our results show that intratumoral injections of TG1024 are safe and well tolerated. The clinical activity of TG1024 observed in this study warrants further investigations...
  17. ncbi request reprint Decreased intraindividual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expression
    J Willers
    Department of Dermatology, University Hospital of Zurich, Switzerland
    J Invest Dermatol 117:1498-504. 2001
    ..These data suggest that treatment approaches aimed at activating specific cytotoxic T lymphocytes are most successful in early disease...
  18. ncbi request reprint HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Switzerland
    Blood 99:609-17. 2002
    ..001). HLA-G up-regulation together with IL-10 expression in CL might additionally contribute to the evasion of immunosurveillance and facilitate the transition from low- to high-grade lymphomas...
  19. ncbi request reprint Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Arch Dermatol 139:1325-32. 2003
    ..It enhances innate and acquired immune responses via endogenous cytokine production and has proven efficacious in clearing superficial basal cell carcinoma (sBCC)...
  20. ncbi request reprint Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2
    Beate Zagrodnik
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Cancer 98:2708-14. 2003
    ..In the current article, the authors report recurrence rates among patients with BCC after superficial radiotherapy as well as Bcl-2 and p53 expression levels stratified by BCC subtype...
  21. ncbi request reprint Recent advances in cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    J Dermatol Sci 48:157-67. 2007
    ....
  22. ncbi request reprint Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod
    Maja Wuest
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, Zurich, Switzerland
    Arch Dermatol Res 299:493-8. 2007
    ..Via induction of Notch signaling imiquimod may exert tumor suppressor function, which together with its proinflammatory properties results in tumor regression...
  23. ncbi request reprint Imiquimod in basal cell carcinoma: how does it work?
    R Dummer
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Br J Dermatol 149:57-8. 2003
    ..Our findings demonstrate that imiquimod-induced BCC regression is associated with a strong activity of the innate immune response, mediated by cells of macrophage-monocyte origin and is associated with the induction of apoptosis...
  24. ncbi request reprint Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients
    Senta M Walton
    Medical Oncology, Department of Internal Medicine, University Hospital Zurich, Raemistrasse 100, CH 8091 Zurich, Switzerland
    J Immunol 177:8212-8. 2006
    ..In addition to the identification of a RAB38/NY-MEL-1-derived immunogenic CD8 T cell epitope, this study is instrumental for both the onset and monitoring of future RAB38/NY-MEL-1-based vaccination trials...
  25. ncbi request reprint Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Blood 104:1631-8. 2004
    ..We demonstrate the induction of humoral immune response to lymphoma tumor-antigen se70-2 after treatment. Our study shows that intralesional injections of TG1042 are both safe and well tolerated...
  26. ncbi request reprint Role of imiquimod in skin cancer treatment
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Am J Clin Dermatol 5:453-8. 2004
    ..This article reviews current literature on the use of imiquimod in the treatment of nonmelanoma and melanoma skin cancer...
  27. pmc Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production
    M Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Am J Pathol 159:817-24. 2001
    ..It is conceivable that HLA-G expression in lung cancer might be one of the ways how the tumor down-regulates host immune response, in addition to interleukin-10 production and HLA class I loss...
  28. ncbi request reprint Successful imiquimod treatment of multiple basal cell carcinomas after radiation therapy for Hodgkin's disease
    Mirjam Beyeler
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich Switzerland
    Eur J Dermatol 15:52-5. 2005
    ..Until now he is in complete remission. However, multiple superficial basal cell carcinomas have developed on irradiation fields that have been successfully treated by imiquimod...
  29. ncbi request reprint Immunotherapy for nonmelanoma skin cancer: does it have a future?
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Switzerland
    Cancer 94:477-85. 2002
    ....
  30. ncbi request reprint Pathogenesis and therapy of cutaneous lymphomas--progress or impasse?
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Exp Dermatol 15:392-400. 2006
    ....
  31. doi request reprint Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography
    Patrick A Oberholzer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 217:351-5. 2008
    ..Baseline staging is important in all melanoma types, including melanoma with unknown primary site (MUP). Staging includes different examination strategies, each with different accuracy...
  32. ncbi request reprint Real-time polymerase chain reaction monitoring of epithelial cell adhesion molecule-induced T-cell stimulation in patients with lung cancer and healthy individuals using LightCycler technology
    Andreas Trojan
    Division of Oncology, Department of Internal Medicine, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    J Immunother 25:264-8. 2002
    ..Our study indicates that quantitative polymerase chain reaction may be a supplement to chromium-release assay for monitoring in vitro expanded CTL precursor reactivity...
  33. ncbi request reprint Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR
    Andreas Trojan
    Division of Oncology, Department of Internal Medicine, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Immunother 26:41-6. 2003
    ..Results from this study indicate that the use of bioinformatics and the PCR-based screening system for the monitoring of T cell reactivity may allow for the identification of novel CTL epitopes...
  34. ncbi request reprint Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer
    Andreas Trojan
    Department of Oncology, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Lung Cancer 44:143-7. 2004
    ..Our results indicate that CD8+ T cells infiltrating the tumor cell nests may be inadequately activated and thus incapable of mounting an effective anti-tumor immune response...
  35. ncbi request reprint Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 207:116-8. 2003
    ..However, the plaque on the face was PUVA resistant. Local imiquimod treatment resulted in the complete clearance of the plaque. The patient has now been in complete remission for 12 months...
  36. ncbi request reprint Pathogenesis of cutaneous lymphomas
    R Dummer
    Department of Dermatology, University of Zurich Medical School, Switzerland
    Semin Cutan Med Surg 19:78-86. 2000
    ..Newly identified molecular disturbances in cutaneous lymphomas might be targeted by specific molecular or immunologic interventions in the future...
  37. ncbi request reprint Exploring primary cutaneous B-cell lymphoma by microarray technology
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    J Invest Dermatol 120:vii-viii. 2003
  38. ncbi request reprint Anti-HIV state but not apoptosis depends on IFN signature in CD4+ T cells
    Annette Audigé
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
    J Immunol 177:6227-37. 2006
    ..We conclude that acute HIV infection of lymphoid tissue results in up-regulation of ISGs in CD4(+) T cells, which induces an anti-HIV state but not apoptosis...
  39. doi request reprint An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 14:856-64. 2008
    ..A topical Toll-like receptor 7 (TLR7) agonist induces regression of cutaneous melanocytic neoplasms. We explored antitumor activity of a systemically administered TLR7 agonist, 852A, in patients with metastatic melanoma...
  40. doi request reprint Green tea extract reduces induction of p53 and apoptosis in UVB-irradiated human skin independent of transcriptional controls
    Christian D Mnich
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Exp Dermatol 18:69-77. 2009
    ..Topical GTE (OM24) reduces UVB-mediated epithelial damage already at low, cosmetically usable concentrations, without tachyphylaxis over 5 weeks, suggesting GTE as suitable everyday photochemopreventive agents...
  41. ncbi request reprint [Perspective of cutaneous lymphoma reserach]
    Reinhard Dummer
    Dermatologische Klinik, Universitatsspital Zurich, Schweiz
    J Dtsch Dermatol Ges 4:492-5. 2006
    ..The new WHO/EORTC classification definitely will facilitate a more detailed investigation of the various subtypes...
  42. ncbi request reprint Standard and experimental therapy in cutaneous T-cell lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    J Cutan Pathol 33:52-7. 2006
    ..Evidence-based treatment recommendation exists but is hampered by the lack of large multicenter randomized trials...
  43. ncbi request reprint Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients
    Alfred Zippelius
    Klinik und Poliklinik für Onkologie, Departement fur Innere Medizin, Universitatsspital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Cancer Immunol Immunother 56:249-58. 2007
    ..Implications for the understanding of spontaneous humoral immune responses are discussed...
  44. pmc Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Mol Ther 18:1244-7. 2010
    ..CLs, in particular B-cell lymphomas with high objective response rates, seem to be excellent targets for this type of immunotherapy...
  45. doi request reprint Evaluation of lymphangiogenic markers in Sézary syndrome
    Maria B Karpova
    Department of Dermatology, University of Zurich, Zurich, Switzerland
    Leuk Lymphoma 52:491-501. 2011
    ..We show for the first time a non-vascular pattern of VEGF-C and VEGFR-3, i.e. their epidermal expression in erythrodermic CTCLs, suggesting their role in lymphocyte trafficking to the skin...
  46. ncbi request reprint The interferon inhibiting cytokine IK is overexpressed in cutaneous T cell lymphoma derived tumor cells that fail to upregulate major histocompatibility complex class II upon interferon-gamma stimulation
    J Willers
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    J Invest Dermatol 116:874-9. 2001
    ..Interferon inhibiting cytokine factor may participate in providing a microenvironment at the tumor site insensitive to interferon-gamma stimulation and thus prevents an efficient local immune response...
  47. ncbi request reprint HLA-G and its KIR ligands in cancer--another enigma yet to be solved?
    Mirjana Urosevic
    J Pathol 196:252-3. 2002
    ..Moreover, a subset of infiltrating cells also expressed HLA-G-recognizing KIR, ILT-2. This editorial discusses the induction of HLA-G and related KIR molecules as another mechanism for tumours to escape immune recognition...
  48. ncbi request reprint Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation
    Sibylla Martinelli
    Department of Pharmacology, University of Bern, CH 3010, Switzerland
    J Biol Chem 279:44123-32. 2004
    ..These data contribute to our understanding regarding changes of gene expression during neutrophil differentiation and IFN-mediated anti-bacterial defense mechanisms...